Eisai Transfers Rights to Receive Royalties Outside of Japan for EZH2 Inhibitor Tazemetostat to Royalty Pharma
- Written by ACN Newswire - Press Releases
Tazemetostat is a first-in-class, oral EZH2 inhibitor discovered by Epizyme,
Read more //?#
.
Leonardo.Ai reveals new brand, expanding its creator-first platform for the next era of generative AI
The company has also launched its developer API to empower creators and builders to integrate AI into their workflows SYDNEY, Australia – 19 Febr...
Psychosocial injury risk starts inside workplace microcultures
Psychological injury is now one of the most expensive categories of workers compensation claims in Australia, with Safe Work Australia reporting t...
2025 Thryv Business and Consumer Report - Australian small businesses show grit under pressure
Australia’s small businesses are powering ahead with optimism, resilience and discipline, however, mounting pressures on costs, wellbeing and cons...
Security by Default: Why 2026 Will Force Organisations to Rethink Cloud and AI
financial accountability to how they run cloud and AI, according to leading Australian systems integrator, Brennan. Based on customer insights...
UNSW launches plan to help Aussie startups scale overseas
UNSW Launches Global Innovation Foundry to Scale 100 Australian Startups Internationally New initiative provides startups and spinouts with direc...
Payroll Under Pressure: Why Mid-Sized SMEs Struggle to Keep Pay Accurate
A year after wage theft reforms came into effect, Australian businesses have increased their focus on payroll compliance, but confidence in pay accu...